共 50 条
- [41] Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progressionCANCER RESEARCH, 2018, 78 (13)Muqbil, IrfanaLi, YiweiBaloglu, ErkanSenapedis, WilliamLandesman, YosefArgueta, ChristianKauffman, MichaelFriedlander, SharonChang, HuaShacham, SharonHeath, ElisabethAzmi, Asfar S.
- [42] Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AMLBLOOD ADVANCES, 2022, 6 (22) : 5938 - 5949Pianigiani, GiuliaGagliardi, AndreaMezzasoma, FedericaRocchio, FrancescaTini, ValentinaBigerna, BarbaraSportoletti, PaoloCaruso, SimonaMarra, AndreaPeruzzi, SaraPetito, EleonoraSpinozzi, GiulioShacham, SharonLandesman, YosefQuintarelli, ConcettaGresele, PaoloLocatelli, FrancoBrunetti, LorenzoMartelli, Maria PaolaFalini, Brunangelo
- [43] Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal CancerGASTROENTEROLOGY, 2021, 161 (01) : 196 - 210Inoue, AkiraRobinson, Frederick S.Minelli, RosalbaTomihara, HideoRizi, Bahar SalimianRose, Johnathon L.Kodama, TakahiroSrinivasan, SanjanaHarris, Angela L.Zuniga, Andy M.Mullinax, Robert A.Ma, XiaoyanSeth, SahilDaniele, Joseph R.Peoples, Michael D.Loponte, SaraAkdemir, Kadir C.Khor, Tin OoFeng, NingpingRoszik, JasonSobieski, Mary M.Brunell, DavidStephan, CliffordGiuliani, VirginiaDeem, Angela K.Shingu, TakashiDeribe, Yonathan LissanuMenter, David G.Heffernan, Timothy P.Viale, AndreaBristow, Christopher A.Kopetz, ScottDraetta, Giulio F.Genovese, GiannicolaCarugo, Alessandro
- [44] XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancerANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1345Quintanal-Villalonga, A.Taniguchi, H.Hao, Y.Chow, A.Zhan, Y. A.Uddin, F.Allaj, V.Manoj, P.Shah, N.Chan, J. M.Offin, M.Ciampricotti, M.Egger, J.Qiu, J.De Stanchina, E.Hollmann, T. J.Koche, R. P.Sen, T.Poirier, J. T.Rudin, C. M.
- [45] XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5ACLINICAL CANCER RESEARCH, 2015, 21 (14) : 3286 - 3297Miyake, TakahitoPradeep, SunilaWu, Sherry Y.Rupaimoole, RajeshaZand, BehrouzWen, YunfeiGharpure, Kshipra M.Nagaraja, Archana S.Hu, WeiCho, Min SoonDalton, Heather J.Previs, Rebecca A.Taylor, Morgan L.Hisamatsu, TakeshiKang, YuLiu, TaoShacham, SharonMcCauley, DilaraHawke, David H.Wiktorowicz, John E.Coleman, Robert L.Sood, Anil K.
- [46] Inhibition of BCL2 and XPO1 demonstrates synergistic effects in triple-negative breast cancer cell linesCANCER RESEARCH, 2024, 84 (06)Jackson, Marilyn MarieSmoots, Stephen G.Dominguez, Adrian T.Dus, EvanBagby, StaceyBinns, CameronPitts, Todd M.Diamond, Jennifer R.
- [47] Nuclear exporter protein XPO1 a novel prognostic and therapeutic target in gastric cancerCANCER RESEARCH, 2018, 78 (13)Muqbil, IrfanaMahdi, ZaidChoudhary, RahmanBaloglu, ErkanSenapedis, WilliamLandesman, YosefShacham, SharonKauffman, MichaelKim, SteveBeydoun, RaficBerri, Richard N.Shields, AnthonyMohammad, Ramzi M.Azmi, Asfar S.
- [48] Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesisTRANSLATIONAL CANCER RESEARCH, 2021, 10 (11) : 4664 - +Zhao, LeiLuo, BaiweiWang, LiangChen, WeiJiang, ManyuZhang, Nengwei
- [49] Targeting metabolic vulnerabilities of endocrine resistant breast cancers using XPO1 and NAMPT inhibition.CANCER RESEARCH, 2021, 81 (13)Zuo, QianyingMogol, AycaImir, OzanLandesman, YosefErdogan, Zeynep Madak
- [50] JAK inhibition as a therapeutic approach to enhance radiation response in rectal cancerCANCER RESEARCH, 2023, 83 (07)Pennel, Kathryn A.Hathakarnkul, PhimmadaAl-Badran, Sara S.Hashmi, UmarHillson, LilyQuinn, Jean A.Jones, LeiaSteele, Colin W.McMillan, Donald C.Park, James H.Sansom, Owen J.Birch, JoannaRoxburgh, Campbell S.Edwards, Joanne